Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GT Biopharma, Inc.GTBP · Entity 7878 | Acting Chief Financial Officer | December 31, 2021 | February 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GT Biopharma, Inc.
Report date December 31, 2021 · Filed February 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.05 · Expires 2031-12-31 | Direct | 227,500 |
Reported balance
After 2021-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-31 · Grant · Acquired 227,500 · Balance 227,500 F1: 33% on the date of grant, 33% on 6/1/22 and 34% on 6/1/23, subject to continued service and subject to full acceleration immediately prior to the consummation of a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: 33% on the date of grant, 33% on 6/1/22 and 34% on 6/1/23, subject to continued service and subject to full acceleration immediately prior to the consummation of a change of control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2021 Filed Feb 14, 2022 21:09 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 227,500 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001654954-22-001631 · section16.xml · derivative · entry 1 Choy Gavin · CIK 0001905561 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,500 Underlying: Common Stock · 227,500 shares Expires 2031-12-31 F1 · derivative.exercise_date: 33% on the date of grant, 33% on 6/1/22 and 34% on 6/1/23, subject to continued service and subject to full acceleration immediately prior to the consummation of a change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.